Sheba Medical Center's utilization of AISAP's AI technology has revolutionized cardiac diagnosis, reducing the time it takes to perform bedside assessments to less than five minutes.
On July 15, 2026, it was announced that AISAP, a point-of-care ultrasound (POCUS) platform cleared by the FDA, has been highlighted as Case Study #5 in a report by the World Health Organization titled "Bridging Theory and Practice." This report provides insights into the practical applications of artificial intelligence in healthcare systems around the globe. AISAP's recognition among numerous evaluated AI companies underscores its impactful collaboration with Sheba Medical Center, a leader in global health care.
The focus of this case study is on the implementation of AISAP's technology in both the internal medicine and emergency departments at Sheba. Between July 2022 and December 2023, AI-enhanced cardiac ultrasounds were conducted on 660 patients by physicians who lacked formal training in sonography. Significant findings from the research, published in the Mayo Clinic Proceedings: Digital Health, indicate that the AI-enhanced Focused Ultrasound (FoCUS) identified clinically important cardiac issues in 193 patients (about 29%). This included 147 new diagnoses (22%) that had not been previously documented, which led to medication adjustments for 49 patients (7%) and 9 patients (1.4%) undergoing interventional procedures. In a more focused group of 117 patients, the FoCUS reached an impressive 100% sensitivity for significant left ventricular dysfunction and maintained a specificity of 96.9%. For aortic stenosis, it also achieved 100% sensitivity with 87.6% specificity when validated against formal echocardiography.
Robert Klempfner, the Chief Medical Officer and Co-Founder of AISAP, stated, "This recognition by the World Health Organization confirms our experience at Sheba: AI-guided POCUS can deliver high-level cardiac diagnostics to clinicians at the patient’s bedside in mere minutes instead of hours. Validated AI is transforming how we provide rapid, expert care across different hospital departments."
The WHO's case study relayed findings from Sheba's clinical study, reporting that over 30% of cases resulted in changes to treatment plans, accelerated discharges, or care transitions, with scans frequently concluding in under five minutes. By the second quarter of 2025, the AISAP platform had facilitated more than 3,000 scans across six departments and the emergency room, with 150 clinicians trained to integrate it into their everyday practices.
Having received FDA clearance in September 2024 (510(k) K234141) for the AISAP CARDIO V1.0 system, AISAP was validated based on a substantial multicenter study in the US that indicated sensitivities and specificities exceeding 93% for identifying significant valvular and ventricular issues, as confirmed by an independent core lab at Mass General Brigham. Additionally, Sheba has documented further operational results from the extensive rollout of the platform, beyond the results of the peer-reviewed study.
The full WHO report, "Bridging Theory and Practice," can be accessed online for more in-depth insights.
AISAP is redefining diagnostic standards through FDA-cleared algorithms integrated into PocusOS™, its AI system designed for use with any point-of-care ultrasound device. The platform sees application in academic medical centers, community facilities, and cardiology practices worldwide, and counts research institutions such as Stanford, Mayo Clinic, Mass General Brigham, Innova, and Jefferson Health among its collaborators. For additional information, visit aisap.ai.
Original content can be viewed for multimedia downloads through available press sources.
